Abstract| Volume 18, ISSUE 6, SUPPLEMENT , S17-S18, June 2016

Successful Technology Transfer of Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Cell Processing From Academia to Industry Enables Scale-Up to Support Global Clinical Trials

      Use of chimeric Antigen Receptor (CAR) targeting CD19 (CTL019) as a cell-based immunotherapy has been reported to have positive results with high complete response rates in relapsed refractory malignancies. Thus far, CTL019 has been processed in an academic center. For large-scale manufacturing of CTL019 and more widespread distribution to patients and physicians, a focus on scalability to meet demands is critical.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect